Obamacare plus the FDA: a recipe for disinvestment

Couple pending price controls and limitations with the utterly (and under the Obami, increasingly) insane FDA regulatory regime and there is precious little room for actual health care innovation.  The result:  massive disinvestment in the sector, with labs closing and companies returning their capital to the shareholders.  It's really the only prudent course.  The capital strike continues....

AN ADMISSION OF DEFEAT? “Announcing layoffs along with a stock buyback – let’s think about what that means. AstraZeneca did that just the other day, and they’re far from the only ones in this industry (or others) spending billions to buy back their own shares while they’re cutting costs elsewhere.”